Pharmacokinetics of high dose etoposide (VP 16-213).
暂无分享,去创建一个
N. Mulder | D. Sleijfer | N H Mulder | D T Sleijfer | P E Postmus | J J Holthuis | W J Van Oort | B Hulshoff | H Verleun | P. Postmus | W. V. van Oort | J. Holthuis | B. Hulshoff | H. Verleun
[1] P. Creaven,et al. EPEG, a new antineoplastic epipodophyllotoxin , 1975, Clinical pharmacology and therapeutics.
[2] E. de Vries,et al. Cyclophosphamide and VP 16-213 with autologous bone marrow transplantation. A dose escalation study. , 1984, European journal of cancer & clinical oncology.
[3] H. Pinedo,et al. Plasma assay for the antineoplastic agent VP 16-213 (etoposide) using high-performance liquid chromatography with electrochemical detection. , 1983, Journal of pharmaceutical and biomedical analysis.
[4] P. Postmus,et al. Remission of brain metastases from small-cell lung cancer after high-dose chemotherapy. , 1984, Annals of internal medicine.
[5] Tore Talseth,et al. Clinical Pharmacokinetics of Hydralazine , 1977 .
[6] J. Whitehouse,et al. ETOPOSIDE: A NEW ANTI-CANCER AGENT , 1981, The Lancet.
[7] O. Selawry,et al. Phase I clinical trial of weekly administration of 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside) (NSC-141540; VP-16-213). , 1974, Cancer chemotherapy reports.
[8] Pharmacokinetics of etoposide in gestochoriocarcinoma. , 1985, Cancer treatment reports.
[9] P. Creaven,et al. Comparison of the human pharmacokinetics of VM-26 and VP-16, two antineoplastic epipodophyllotixin glucopyranoside derivatives. , 1975, European journal of cancer.
[10] G R Wilkinson,et al. Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients. , 1984, Cancer research.
[11] E. Benfenati,et al. Metabolic studies of a podophyllotoxin derivative (VP16) in the isolated perfused liver. , 1985, Xenobiotica; the fate of foreign compounds in biological systems.
[12] D. Perrier,et al. Noncompartmental determination of the steady-state volume of distribution for any mode of administration. , 1982, Journal of pharmaceutical sciences.
[13] J. Hainsworth,et al. High-dose VP-16-213 and autologous bone marrow transplantation for refractory malignancies: a phase I study. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] R. Wittes,et al. Etoposide (VP-16-213). Current status of an active anticancer drug. , 1985, The New England journal of medicine.
[15] P. Postmus,et al. Penetration of VP 16-213 into cerebrospinal fluid after high-dose intravenous administration. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.